Core Viewpoint - The Hong Kong Innovative Drug ETF managed by Penghua experienced a 4.40% increase in value on November 13, with a trading volume of 177 million yuan, despite a reduction in shares by 25 million to a total of 678 million shares [1] Group 1: Fund Performance - The fund's performance benchmark is the Guozheng Hong Kong Stock Connect Innovative Drug Index return (adjusted for exchange rates) [1] - Since its establishment on August 20, 2025, the fund has recorded a return of -5.05% [1] - Over the past month, the fund's return has been -0.05% [1] Group 2: Fund Management - The fund is managed by Penghua Fund Management Co., Ltd. [1] - The fund managers are Lin Song and Zhang Yuxiang [1] Group 3: Share and Asset Information - The latest net asset value of the fund is 644 million yuan [1] - In the last 20 trading days, the fund's shares have increased by 84 million [1]
11月13日港股创新药ETF鹏华（159286）份额减少2500.00万份
Xin Lang Cai Jing·2025-11-14 01:11